-
Happy Birthday ICMag! Been 20 years since Gypsy Nirvana created the forum! We are celebrating with a 4/20 Giveaway and by launching a new Patreon tier called "420club". You can read more here.
-
Important notice: ICMag's T.O.U. has been updated. Please review it here. For your convenience, it is also available in the main forum menu, under 'Quick Links"!
:::::::Indiana Cannabis Reform Legislation::::::
- Thread starter pipeline
- Start date
13News investigation finds some Delta-8 products exceed state’s THC limit, underscoring need for regulation
The products can get users high and are easily accessible – even for minors. But testing finds many of the products contain THC that exceeds Indiana’s legal limit.
www.wthr.com
Multiple States Across The Country See Record-Breaking Marijuana Sales To Close Out 2023
More than a half dozen U.S. states where marijuana is legal notched record-breaking monthly sales in December, with many relatively new adult-use cannabis markets continuing to expand and American shoppers in general stepping up holiday spending. Most of the monthly sales records were seen in...www.marijuanamoment.net
Every time you decide to buy something, its like voting for it. The amount of revenue shows that the people are supportive of adult-use cannabis. Having all these states continuing to function allowing adult-use will display the power of the people.
There would be quite an uprising if the government ever decides to take away the right to use this medicine from citizens of legal states.
Its called God showing up and blessing it, we should give thanks! All the kind, dedicated souls who worked to get this done, as well as all the people who have been outspoken to educate others deserve recognition. People making purchases have cast their vote! Yes for cannabis!
Cannabinoids in breast milk | Kalapa Clinic
Not everybody in the world known that there are cannabinoids in breast milk. Studies state that we are born with cannabinoid receptors.
So the government has legalized taking bribe money. These business lobby groups heavily influence lawmakers. A representative from the Indiana Chamber of Commerce testified at a committee hearing for a cannabis bill last year, and they said they needed more research to be done before they would be able to agree to legalized medical cannabis.
The insurance companies are what are telling these businesses to vote this way in the chamber of commerce. So the real power structure is becoming visible. The ones who have the most representation and power in the lawmaking process are big banks who own insurance companies. They dictate to the busness owners how they are going to hire manage employees. The businesses then have to vote that way in the Board of the Chamber of commerce. Then the Chamber of Commerce works to lobby lawmakers to get policies which align which the insurance companies.
The lamakers respond to the advice of the big business lobby groups and ignore the will of the people.
Liberty, natural medicine and the welfare of the people are lost, and they are straight going for the money.
www.indianachamber.com
The insurance companies are what are telling these businesses to vote this way in the chamber of commerce. So the real power structure is becoming visible. The ones who have the most representation and power in the lawmaking process are big banks who own insurance companies. They dictate to the busness owners how they are going to hire manage employees. The businesses then have to vote that way in the Board of the Chamber of commerce. Then the Chamber of Commerce works to lobby lawmakers to get policies which align which the insurance companies.
The lamakers respond to the advice of the big business lobby groups and ignore the will of the people.
Liberty, natural medicine and the welfare of the people are lost, and they are straight going for the money.
Indiana Chamber Foundation Funds Vital Policy Research
The Indiana Chamber Foundation funds practical policy research, initiates actions and seeks solutions that positively impact Indiana’s economic future.
www.indianachamber.com
FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom
The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom. FDA Deputy Commissioner for Policy...
FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom
Published
4 seconds ago
on
February 28, 2024
By
Kyle Jaeger
The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom.
FDA Deputy Commissioner for Policy, Legislation, and International Affairs Kimberlee Trzeciak discussed the agency’s cannabis and kratom interests during a webinar hosted by the Alliance for a Strong FDA this month.
Asked about issues that are “top of mind” for the agency in 2024 and where officials hope to engage with Congress, Trzeciak said that later this year or next year FDA wants to address setting up “an appropriate regulatory framework for CBD.”
Later in the conversation, the FDA official was asked specifically about how the agency is “prioritizing” its work on cannabis and kratom regulations, and she said officials are taking a number of factors into consideration as they work to address the substances.
“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” she said. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”
“Based on what we know about CBD in particular, we do not think that those products would be able to meet the safety standards that we have in place for foods and dietary supplements today,” she said, referencing the agency’s position after it declined to enact regulations for the non-intoxicating cannabinoid that was legalized under the 2018 Farm Bill.
“What can we do in terms of regulatory tools to ensure that this product is going to be marketed that consumers are clearly aware of what the product is, what is in it and making sure that we have basic information about the marketplace?” Trzeciak said. “I like to think of it as the common regulatory tool that we have across the other products that we regulate.”
She added that FDA wants to “work with Congress on this effort,” including possible rulemaking around CBD product labeling and packaging.
“For example, how can we ensure that the agency knows if there are adverse events that are being reported, so we can identify those trends, making sure that the product is being manufactured or produced in a way that’s safe and quality?” she said.
Kratom reform advocates say the deputy commissioner’s comments represent a “shift” in the agency’s policy perspective on the issue. Historically, FDA hasn’t engaged in the kratom debate as actively as other agencies such as the National Institute on Drug Abuse (NIDA).
Meanwhile, FDA has faced criticism from hemp stakeholders and lawmakers over its prior decision not to regulate CBD, despite its prevalence in the marketplace. But it’s insisted that it will need additional congressional authorization in order to develop such regulations.
In a recent letter addressed to House Energy and Commerce Committee leaders, 28 state and national nonprofits focused on hemp and dietary supplements said that “the time for a hearing has never been riper” to examine regulatory pathways that FDA could enact to allow for the lawful marketing of hemp products for humans and animals.
The committee responded to FDA’s inaction last summer by putting out a Request for Information (RIF) from experts on the best path forward for regulating hemp, with hundreds of respondents sharing their perspective and recommendations.
With respect to congressional action, Sens. Ron Wyden (D-OR), Rand Paul (R-KY) and Jeff Merkley (D-OR), along with Rep. Earl Blumenauer (D-OR), filed legislation last July that would remove regulatory barriers that FDA claims prevents it from allowing the hemp marketing.
The House Oversight and Accountability Subcommittee on Health Care and Financial Services also held a hearing on FDA inaction over CBD last year, a first-of-its-kind meeting where bipartisan members strongly criticized the agency’s position.
Meanwhile, the National Association of State Departments of Agriculture (NASDA) is separately calling on Congress to increase the THC limit for legal hemp as one of their 2024 policy priorities.
The 0.3 percent THC limit for hemp that was imposed under the 2018 Farm Bill that federally legalized the crop has long been subject to criticism from stakeholders and lawmakers across the aisle. And one Justice Department researcher recently called into question the rationale for the restriction, suggesting it was arbitrarily decided based on a 1950s-era article that was adopted into federal statute.
The Congressional Research Service (CRS) recently outlined how differing policy priorities among industry stakeholders could complicate the task of updating the next farm bill’s hemp provisions, but there are several areas of agreement within the top industry groups.
One of those shared interests is amending the law to raise the THC limit to one percent for compliant hemp—a proposal that was also addressed in a standalone bill from Rep. Chellie Pingree (D-ME) in 2022.
It’s unclear if congressional lawmakers will ultimately tackle the Farm Bill this year. The 2018 version was set to expire at the end of last year, but it was extended under a bill President Joe Biden signed.
Meanwhile, FDA has also been engaged in other drug policy reform debates amid an ongoing federal review into marijuana scheduling, which prompted the agency to recommend. moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).
FDA recently highlighted its scientific review into marijuana—a process that involved a comprehensive analysis of research, as well looking at hundreds of posts on social media platforms to see how consumers described cannabis’s therapeutic impact.
Earlier this month, FDA officials also joined scientists at a public meeting on next steps for conducting research to develop psychedelic medicines.
The meeting came months after FDA issued historic draft guidance on psychedelics studies, providing scientists with a framework to carry out research that could lead to the development of novel medicines.
To that end, FDA also recently accepted an application to review MDMA-assisted therapy as treatment option for post-traumatic stress disorder (PTSD), agreeing to carry out the analysis on an expedited basis.
lower is actually illegal to possess here. They are unable to run enough tests, and the testing capability is limited to the accuracy down to 1% using the cheaper testing methods they use.
The manufacturers actually have a very difficult time clearing the 0.3% threshold becuase its set so artificially low. They actually are violating the law at times in production, and some of the products you can purchase were tested by WISH 13 news in an investigative report and were found to have 1-2% delta 9 THC.
I could purchase it online and just keep it at home. Yeah its a crazy situation Hemp is legal federally yet the state doesn't allow it.
Then the medical cannabis which contains THC is legal in some states yet not legal federally.
The manufacturers actually have a very difficult time clearing the 0.3% threshold becuase its set so artificially low. They actually are violating the law at times in production, and some of the products you can purchase were tested by WISH 13 news in an investigative report and were found to have 1-2% delta 9 THC.
I could purchase it online and just keep it at home. Yeah its a crazy situation Hemp is legal federally yet the state doesn't allow it.
Then the medical cannabis which contains THC is legal in some states yet not legal federally.
UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform And U.S. Psychedelics Movement
The United Nations’s (UN) drug control body is reiterating that it considers legalizing marijuana for non-medical or non-scientific purposes a violation of international treaties, though it also said it appreciates that Germany’s government scaled back its cannabis plan ahead of a recent vote...
UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform And U.S. Psychedelics Movement
Published
5 seconds ago
on
March 6, 2024
By
Kyle Jaeger
The United Nations’s (UN) drug control body is reiterating that it considers legalizing marijuana for non-medical or scientific purposes a violation of international treaties, though it also said it appreciates that Germany’s government scaled back its cannabis plan ahead of a recent vote. The global narcotics agency is also taking note of the psychedelics policy reform movement in U.S. states.
This is mostly par for the course for the International Narcotics Control Board (INCB), which has routinely criticized countries for allowing the enactment of cannabis legalization due to their obligations under various Single Convention treaties going back to 1961. But as Germany entered the fold, and the U.S. has continued to move toward marijuana and psychedelics reform, the body is again making its disappointment known.
INCB’s 2023 annual report, which was published on Tuesday, “underscores” that member nations are required to “take such legislative and administrative measures as may be necessary” to criminalize “the production, manufacture, export, import, distribution of, trade in, use and possession of drugs” such as marijuana under decades-old treaty agreements.
“The Board continues to reiterate its concern regarding the legalization of the use of cannabis for non-medical and non-scientific purposes in several jurisdictions, with other jurisdictions considering similar action,” it said.
To that point, INCB also included a recommendation in the latest report to recall an analysis from its 2022 report that, at one point, suggested that the U.S. is out of compliance with drug treaty obligations because the federal government is passively allowing states within the country to legalize marijuana.
“The apparent tension between these provisions and the trend towards legalization must be addressed by the signatories to the three drug control conventions,” it said.
Meanwhile, the new report also discusses the board’s ongoing monitoring of efforts to legalize marijuana in Germany. The country’s parliament officially approved a bill to legalize cannabis nationwide last month.
“The Board has had ongoing discussions with the authorities in Germany and has taken note of the evolution of the originally planned control measures following concerns expressed by the European Commission, in particular with respect to the provisions on the sale of cannabis in speciality shops to adults for non-medical purposes,” it said.
That’s in reference to changes to the Germany government’s legalization plan that makes it so possession and home cultivation would become legal, while authorizing social clubs to distribute marijuana to members, but not establishing a full-scale commercial market right away.
Overall, while German supporters have said legalization would take effect in April if the legislation is enacted, there are questions about that timeline. The country’s Bundesrat may move to refer the legislation to a mediation committee to address criminal justice-related implications of the law, which could mean several months of additional discussion.
In the U.S., INCB recognized that while “cannabis remains subject to the highest level of control under the Controlled Substances Act, use of the drug has been legalized in several states for non-medical purposes.”
“The Board has repeatedly expressed its concern that these developments may be inconsistent with the country’s legal obligations as a party to the three international drug conventions,” it said.
“The Board continues to maintain a constructive dialogue with the Government of the United States on these matters,” it added.
The report further notes that President Joe Biden’s mass pardons for federal marijuana possession offenses are actively “being implemented” by the Justice Department.
“While the presidential pardon does not expunge the existing conviction, it removes civil or legal restrictions, such as on the rights to vote, hold office or sit on a jury, and lifts barriers to housing, employment and educational opportunities,” it says.
Notably, INCB did not mention the parallel presidential directive that’s underway to review the scheduling status of cannabis under federal law.
The reason that lack of mention stands out is because supporters and opponents of rescheduling under U.S. law, as recommended by the U.S. Department of Health and Human Services (HHS), have made competing arguments about the influence of international treaty obligations in the final decision that the Drug Enforcement Administration (DEA) is expected to hand down.
For example, a Democratic congresswoman recently implored DEA to “reject any argument” that rescheduling marijuana under federal law would constitute a violation of international treaty obligations. She also asked the agency to reveal a list of any “outside partners” it has met with to discuss the global implications of a potential cannabis reclassification.
Legal experts recently released an opinion that disputes that assessment. In fact, they argued that a move to Schedule III would better uphold the country’s broader obligations under international law to regulate cannabis in a way that protects public health and safety.
Among those who’ve raised concerns about treaty obligations blocking a move to Schedule III is Rep. Andy Harris (R-MD), who raised the issue in a letter sent to DEA Administrator Anne Milgram late last month, claiming that any reclassification that puts marijuana outside of Schedule I or Schedule II “would constitute a violation of the Single Convention,” referring to the 1961 United Nations (UN) Single Convention on Narcotic Drugs.
But as a coalition of 12 senators pointed out in a separate letter to Milgram a week earlier, the UN has since revised global cannabis scheduling policies and allowed other member states, such as Canada, to legalize and regulate marijuana without penalty. Those lawmakers urged DEA to legalize marijuana completely.
Additionally, INCB in its new report said that it is monitoring psychedelics policy developments in the U.S. and in other countries, including the legalization of psilocybin services in Oregon and a broader class of psychedelics in Colorado.
“A growing interest in the therapeutical potential of psychedelic drugs and the potential risks in their unregulated use has also been noted,” the report said. “While clinical studies on the use of psychedelics are conducted in some countries, most of the health, wellness and tourism businesses involving the use of psychedelics have been operating without much regulatory oversight. Unsupervised and experimental use of those substances, even in microdoses as self-medication, may put some vulnerable populations at risk.”
Couldn't adult-use legalization be considered medicinal since cannabis is a medicine?
I really don't see where the contradiction exists except in the corrupt minds of the controlling corporate elite in high authority positions.
See, everyone has been trained to think of cannabis as a drug of abuse, therefore, everyone will suffer now because, supposedly, the people are incapable of using cannabis as a medicine without a doctor's guidance. This is not true, due to the favorable safety profile of cannabis. Its a valuable therapeutic that can be used in a wide range of dosages with little adverse or side effects.
Why can't we just say, alright adults are able to purchase or produce cannabis for use as medicine. Then we can go from there allowing people to live dignified lives where they are responsible for using cannabis in a way that is helpful for them.
Liberty or death. Where is the love?
Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor
The Indiana legislature has sent a bill to the governor’s desk that includes provisions to fund clinical research trials into psilocybin. The House and Senate both passed the underlying legislation on health care issues, which was amended to add the psychedelics language, last week. The reform...
www.marijuanamoment.net
Indiana Governor Signs Psilocybin Research Funding Bill With Focus On Veterans And First Responders
The governor of Indiana has signed a bill that includes provisions to fund clinical research trials on the therapeutic benefits of psilocybin. Gov. Eric Holcomb (R) approved the legislation, which broadly focuses on health care issues, but which was amended to add the psychedelics language, last...
www.marijuanamoment.net
Event Details
INDIANA NORML 50TH ANNIVERSARY PRESENTED BY VIRIDIS LAW @ HI-FI ANNEX INDIANAPOLIS
WITH DJ INDYCA, LESLIE RED, OK BOOMER, ASSORTED FLAVORS, BULLETPROOF & THE FOOL
DOORS: 4:20 PM, EVENT: 5:00 PM
GENERAL ADMISSION, LIMITED SEATING.
AGE RESTRICTIONS: 21+
ALL TICKETS ARE NON TRANSFERABLE AND NON REFUNDABLE. SUPPORT ACTS ARE SUBJECT TO CHANGE.
----------------------------
INDIANA NORML 50TH ANNIVERSARY
Join us in celebrating a significant milestone in the fight for cannabis advocacy as Indiana NORML marks its 50th anniversary!
Our mission has been steadfast—to move public opinion in favor of the responsible use of cannabis by adults and to be the voice for consumers seeking safe, convenient, and affordable access to high-quality cannabis.
We are called to break the chains of outdated cannabis laws. Indiana NORML is on a mission to turn the tide, armed with a staggering truth: only 9% of Hoosiers are on board with the current cannabis regulations. This isn't just a statistic; it's a call to action.
Imagine a future where the voice of the people shapes policies, where the impact on minority communities is a priority. Indiana NORML is unleashing a powerhouse plan—educational blitzes, powerful engagements with industry professionals, and a strategic legislative push. This isn't just about cannabis; it's about justice, health, and a state united for change.
Stand with us as we turn the page on archaic regulations and write a new chapter for Indiana—one that echoes with the collective power of a community demanding progress. Let's make history together.
Live Entertainment: DJ Indyca LIVE
Experience the vibrant beats of DJ Indyca LIVE throughout the event, creating an atmosphere of celebration and unity.
Stay Connected:
For more information and updates, visit our official site: INDIANANORML.ORG
